2019至2022年美国男男性行为者及男男性行为兼女性性行为者中的性传播感染/艾滋病病毒检测、性传播感染与艾滋病病毒暴露前预防用药情况
利用美国大型行政数据集HealthVerity,评估2019至2022年首次就诊的81 716例15-64岁男男性行为者及男男性行为兼女性性行为者中性传播感染/艾滋病病毒检测、沙眼衣原体和淋病阳性率及艾滋病病毒暴露前预防用药情况。结果显示检测率不足六成,暴露前预防用药使用率30.9%、启动率18.1%。作者认为需定期评估检测情况并紧急推动暴露前预防用药。
要点
- 首次就诊时沙眼衣原体检测率57.9%、淋病58.1%、梅毒52.2%、艾滋病病毒检测55.5%。
- 无艾滋病病毒感染者中暴露前预防用药使用率30.9%、启动率18.1%。
- 接受沙眼衣原体和淋病检测者中48%仅检测生殖道部位,25%检测3个解剖部位。
核心结论
- 研究呈现了男男性行为者及男男性行为兼女性性行为者在私立门诊场所首次就诊时接受的医疗服务现状。
- 作者认为由于感染率高,需定期评估性传播感染/艾滋病病毒检测情况,并紧急推动私立机构中男男性行为者及男男性行为兼女性性行为者的艾滋病病毒暴露前预防用药。
研究设计与样本
- 利用美国大型行政数据集HealthVerity,纳入2019至2022年首次就诊(索引日期)时处于艾滋病病毒和性传播感染风险增加的15-64岁男男性行为者及男男性行为兼女性性行为者共81 716例。
主要发现
- 首次就诊时沙眼衣原体检测率为57.9%、淋病检测率为58.1%、梅毒检测率为52.2%。
- 在无艾滋病病毒感染者中,艾滋病病毒检测率为55.5%、艾滋病病毒暴露前预防用药使用率为30.9%、暴露前预防用药启动率为18.1%。
- 在接受沙眼衣原体和淋病检测的患者中,48%仅检测生殖道部位,25%检测直肠、咽部和泌尿生殖道3个解剖部位。
- 沙眼衣原体直肠感染阳性率为9.8%,淋病直肠感染阳性率为7.3%,淋病咽部感染阳性率为5.3%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Routine sexually transmitted infection and human immunodeficiency virus (STI/HIV) testing and HIV pre-exposure prophylaxis (PrEP) use are recommended for men who have sex with men (MSM) at increased risk of HIV. METHODS: Using HealthVerity, a large administrative dataset in the United States, we assessed STI/HIV testing, chlamydia and gonorrhea positivity by specimen type, and HIV PrEP use among MSM and men who have sex with men and women (MSMW) at their first visits (index date) for those at increased risk of HIV and STIs from 2019 through 2022. RESULTS: Among 81 716 MSM and MSMW aged 15-64 years at their index date visit, STI testing rates were 57.9% for chlamydia, 58.1% for gonorrhea, and 52.2% for syphilis testing, respectively; 55.5%, 30.9%, and 18.1% had HIV testing, HIV PrEP use, and PrEP initiation, respectively, among the patients who did not have HIV. Of patients with chlamydia and gonorrhea testing, 48% were tested from the genital site only and 25% from 3 anatomic sites (rectal, pharyngeal, and urogenital). Chlamydia and gonorrhea positivity was 9.8% for chlamydia rectal infection, 7.3% for gonorrhea rectal infection, and 5.3% for gonorrhea pharyngeal infection. CONCLUSIONS: Our results present current medical services provided during initial clinic visits for MSM and MSMW in private outpatient settings. Our study suggests that the assessment of STI/HIV testing is periodically needed due to the high prevalence of infection, and efforts to promote HIV PrEP for MSM and MSMW in private settings are urgently needed.
引用
- Tao G, Patel CG, He L, et al. Sexually Transmitted Infection (STI)/HIV Testing, STIs, and HIV Pre-exposure Prophylaxis Use Among Men Who Have Sex With Men and Men Who Have Sex With Men and Women in the United States, 2019-2022. Clin Infect Dis. 2026. PMID: 38857177. doi:10.1093/cid/ciae314
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。